Sun Pharma aims 'low-to-mid teens' growth in consolidated revenues in FY20

01 Aug 2019 Evaluate

Sun Pharmaceutical Industries is gradually ramping up its speciality business across global markets as it aims to clock ‘low-to-mid teens’ growth in consolidated revenues in the current fiscal (FY20). The company is focused at growing each of its business verticals faster than the market in which it operates.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1694.65 -33.80 (-1.96%)
02-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1694.65
Dr. Reddys Lab 1217.60
Cipla 1193.40
Zydus Lifesciences 864.25
Lupin 2276.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×